Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.59
+0.17 (0.70%)
Nov 21, 2024, 1:14 PM EST - Market open
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 38.9, with a low estimate of 22 and a high estimate of 90. The average target predicts an increase of 58.19% from the current stock price of 24.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DNLI stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +266.00% | Nov 7, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $40 → $45 | Strong Buy | Maintains | $40 → $45 | +83.00% | Nov 1, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +13.87% | Oct 11, 2024 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $35 | Buy | Reiterates | $35 | +42.33% | Sep 9, 2024 |
Financial Forecast
Revenue This Year
17.54M
from 330.53M
Decreased by -94.69%
Revenue Next Year
67.30M
from 17.54M
Increased by 283.75%
EPS This Year
-2.70
from -1.06
EPS Next Year
-2.79
from -2.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 47.3M | 164.3M | 545.1M | ||
| Avg | 17.5M | 67.3M | 172.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -85.7% | 837.1% | 710.0% | ||
| Avg | -94.7% | 283.8% | 156.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.29 | -2.13 | -0.61 | ||
| Avg | -2.70 | -2.79 | -2.28 | ||
| Low | -2.85 | -3.27 | -3.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.